ADAR1 Capital Management, LLC bought $35K of MTRI stock
By AlphaYouPublished Form 4
ADAR1 Capital Management, LLC; Schneeberger Daniel
Reporting filer
ADAR1 Capital Management, LLC reported buying 2,640 shares of InMed Pharmaceuticals Inc. for about $35K ($13.10 a share on average). Form 4 filed Nov 10, 2026 lists 1 entry.
- Disclosed
- Nov 10, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Shares | ADAR1 Capital Management, LLC; Schneeberger Daniel | 2026-11-05 | P | Purchase | 2640 | 13.0953 | 98,297 | 5 days | Filed terms
|
Common Shares
- Owner
- ADAR1 Capital Management, LLC; Schneeberger Daniel
- Date
- 2026-11-05
- Code
- P
- Action
- Purchase
- Quantity
- 2640
- Price
- 13.0953
- Following holdings
- 98,297
- Reporting delay
- 5 days
- Filed terms and references
Filed terms
- security Title: Common Shares
- transaction Date: 2026-11-05
- transaction Form Type: 4
- transaction Code: P
- equity Swap Involved: 0
- transaction Timeliness:
- transaction Shares: 2640
- transaction Price Per Share: 13.0953
- id: F1
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 98297
- id: F2
- direct Or Indirect Ownership: I
- nature Of Ownership: See Footnote
- id: F3
- id: F4
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- ADAR1 Capital Management, LLC: 10% owner.
- Schneeberger Daniel: 10% owner.
- F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.9500 to $13.3000, inclusive. Each Reporting Person undertakes to provide to Mentari Therapeutics, Inc., any security holder of Mentari Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2: On November 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its outstanding common stock. The transaction reported herein occurred on November 5, 2026, after giving effect to the reverse stock split. On November 6, 2026, the Issuer completed its previously announced merger transaction and changed its name from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc. and its trading symbol from INM to MTRI. Following completion of the merger and related transactions, the Reporting Persons ceased to beneficially own more than 10% of the Issuer's outstanding common stock and are no longer subject to Section 16.
- F3: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
- F4: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Original sources
Prepared automatically from public filing data. Report a correction.